FDA approves nateglinide for treatment of type 2 diabetes.
T R
TR
Lieder
D003510:Cyclohexanes / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D000077715:Nateglinide; D010649:Phenylalanine